131 related articles for article (PubMed ID: 8961974)
21. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
22. Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma.
Weintraub M; Revel-Vilk S; Charit M; Aker M; Pe'er J
J Pediatr Hematol Oncol; 2007 Sep; 29(9):646-8. PubMed ID: 17805043
[TBL] [Abstract][Full Text] [Related]
23. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.
Yagita M; Ieki Y; Onishi R; Huang CL; Adachi M; Horiike S; Konaka Y; Taki T; Miyake M
Int J Oncol; 1998 Jul; 13(1):91-6. PubMed ID: 9625808
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism.
Sleiman RJ; Catchpoole DR; Stewart BW
Br J Cancer; 1998; 77(1):40-50. PubMed ID: 9459144
[TBL] [Abstract][Full Text] [Related]
25. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach.
Kagan VE; Yalowich JC; Borisenko GG; Tyurina YY; Tyurin VA; Thampatty P; Fabisiak JP
Mol Pharmacol; 1999 Sep; 56(3):494-506. PubMed ID: 10462537
[TBL] [Abstract][Full Text] [Related]
26. Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species.
Papież MA; Krzyściak W; Szade K; Bukowska-Straková K; Kozakowska M; Hajduk K; Bystrowska B; Dulak J; Jozkowicz A
Drug Des Devel Ther; 2016; 10():557-70. PubMed ID: 26893544
[TBL] [Abstract][Full Text] [Related]
27. Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro.
Lowis SP; Newell DR; Pearson AD
Eur J Cancer; 1995; 31A(4):622-6. PubMed ID: 7576982
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia with t(11;19)(q23;p13) developing in an adult T-cell leukemia patient treated with combined chemotherapy including etoposide.
Kanemura N; Tsurumi H; Hara T; Yamada T; Sawada M; Naito T; Moriwaki H
Int J Hematol; 2001 Dec; 74(4):475-6. PubMed ID: 11794709
[No Abstract] [Full Text] [Related]
29. Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression.
Hashimoto H; Chatterjee S; Berger NA
Cancer Res; 1995 Sep; 55(18):4029-35. PubMed ID: 7664276
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT
N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468
[TBL] [Abstract][Full Text] [Related]
31. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
Qiu J; Catapano CV; Fernandes DJ
Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
[TBL] [Abstract][Full Text] [Related]
32. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
33. Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.
Yang J; Bogni A; Cheng C; Bleibel WK; Cai X; Fan Y; Yang W; Rocha JC; Pei D; Liu W; Dolan ME; Pui CH; Relling MV
Clin Pharmacol Ther; 2008 Dec; 84(6):691-7. PubMed ID: 18509329
[TBL] [Abstract][Full Text] [Related]
34. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
35. Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment.
Bower M; Parry P; Gibbons B; Amess J; Lister TA; Young BD; Evans GA
Leukemia; 1994 Feb; 8(2):226-9. PubMed ID: 8309246
[TBL] [Abstract][Full Text] [Related]
36. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
37. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
38. Quantification of hprt gene deletions mediated by illegitimate V(D)J recombination in peripheral blood cells of humans.
Fuscoe JC; Vira LK; Collard DD; Moore MM
Environ Mol Mutagen; 1997; 29(1):28-35. PubMed ID: 9020304
[TBL] [Abstract][Full Text] [Related]
39. V(D)J recombinase-mediated HPRT mutations in peripheral blood lymphocytes of normal children.
Finette BA; Poseno T; Albertini RJ
Cancer Res; 1996 Mar; 56(6):1405-12. PubMed ID: 8640832
[TBL] [Abstract][Full Text] [Related]
40. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
